Our reviews

Full list:

By subtopic:

A. Cardiovascular Disease: Primary Prevention (64)
Prevention (64)
A.1 Drugs (14)
A.1.1 Antiplatelets (0)
A.1.2 Lipid Lowering (7)
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events
Fibrates for primary prevention of cardiovascular disease events
Fibrates for secondary prevention of cardiovascular disease and stroke
Interventions to improve adherence to lipid-lowering medication
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Statins for the primary prevention of cardiovascular disease
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia
A.1.3 Other (7)
Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease
Colchicine for prevention of cardiovascular events
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Homocysteine-lowering interventions for preventing cardiovascular events
Hormone therapy for preventing cardiovascular disease in post-menopausal women
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
Vitamin K for the primary prevention of cardiovascular disease
A.2 Lifestyle (41)
A.2.1 Dietary (23)
Reduced or modified dietary fat for preventing cardiovascular disease
Dietary advice for reducing cardiovascular risk
Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases (protocol stage)
Dietary fibre for the primary prevention of cardiovascular disease
Intermittent fasting for the prevention of cardiovascular disease
Nut consumption for the primary prevention of cardiovascular disease
Reduction in saturated fat intake for cardiovascular disease
Effects of total fat intake on bodyweight in children
Effects of total fat intake on body weight
Effects of total fat intake on body fatness in adults
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease
Green and black tea for the primary prevention of cardiovascular disease
Increased consumption of fruit and vegetables for the primary prevention of cardiovascular diseases
Interventions for increasing fruit and vegetable consumption in children aged five years and under
High versus low-added sugar consumption for the primary prevention of cardiovascular disease
Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk
Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Reduced dietary salt for the prevention of cardiovascular disease
Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases
Vitamin C supplementation for the primary prevention of cardiovascular disease
A.2.2 Exercise (9)
Exercise for people with high cardiovascular risk
Face-to-face interventions for promoting physical activity
Face-to-face versus remote and web 2.0 interventions for promoting physical activity
High-intensity interval training for reducing cardiometabolic syndrome in healthy but sedentary populations (protocol stage)
Interventions for promoting physical activity
Qigong for the primary prevention of cardiovascular disease
Remote and web 2.0 interventions for promoting physical activity
Tai chi for primary prevention of cardiovascular disease
Yoga for the primary prevention of cardiovascular disease
A.2.3 Other lifestyle interventions (9)
Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years
Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years
Do diet and physical activity strategies help prevent obesity in children (aged 0 to 18 years)?
Drug interventions for the treatment of obesity in children and adolescents
Meditation for the primary and secondary prevention of cardiovascular disease (protocol stage)
Multiple risk factor interventions for primary prevention of coronary heart disease
Parent-only interventions for childhood overweight or obesity in children aged 5 to 11 years
Surgery for the treatment of obesity in children and adolescents
A.3 Psychological (1)
Psychological interventions for depression and anxiety in patients with coronary heart disease, heart failure or atrial fibrillation (protocol stage)
A.4 Education or Counselling (0)
A.5 Complementary treatments (3)
Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors
Niacin for primary and secondary prevention of cardiovascular events
Selenium supplementation for the primary prevention of cardiovascular disease
A.6 Policy Related Interventions (0)
A.6.1 Food policy initiatives (0)
A.6.2 Health promotion campaigns (0)
A.6.3 Social & economic developments (0)
A.7 Organisational/Health System Interventions (2)
Risk scoring for the primary prevention of cardiovascular disease
Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease
A.8 Other interventions (3)
The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery
Influenza vaccines for preventing cardiovascular disease
Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults
B. Stable Ischemic Heart Disease (secondary prevention, treatment, control) (52)
B.1 Drugs (15)
B.1.1 Antiplatelets (3)
Antithrombotic treatment following coronary artery bypass surgery: a network meta-analysis (protocol stage)
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events
Ticlopidine versus oral anticoagulation for coronary stenting
B.1.2 Anticoagulants (3)
Direct thrombin inhibitors and factor Xa inhibitors for acute coronary syndromes: a network meta-analysis (protocol stage)
Factor Xa inhibitors for acute coronary syndromes
Vitamin K for improved anticoagulation control in patients receiving warfarin
B.1.3 Adrenergic agents (1)
B.1.3.1 Beta-blockers (1)
Beta-blockers in patients without heart failure after myocardial infarction
B.1.4 Antibiotics (1)
Antibiotics for secondary prevention of coronary heart disease
B.1.5 Lipid Lowering drugs (0)
B.1.6 Nitrates (1)
Niacin for primary and secondary prevention of cardiovascular events
B.1.7 Other (6)
Chinese herbal medicine suxiao jiuxin wan for angina pectoris
Colchicine for the primary prevention of cardiovascular events (protocol stage)
Interleukin-receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases (protocol stage)
Ranolazine for stable angina pectoris
Traditional Chinese herbal products for stable angina
Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention
B.2 Lifestyle (2)
B.2.1 Diet (2)
Low glycaemic index diets for the prevention of cardiovascular disease
Whole grain cereals for the primary or secondary prevention of cardiovascular disease
B.2.2 Exercise (0)
B.3 Rehabilitation (8)
Effectiveness of social network interventions to support cardiac rehabilitation and secondary prevention in the management of people with heart disease (protocol stage)
Exercise-based cardiac rehabilitation for adults with stable angina
Exercise-based cardiac rehabilitation for coronary heart disease
Home-based versus centre-based cardiac rehabilitation
Music for stress and anxiety reduction in coronary heart disease patients
Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews
Interventions to promote patient utilisation of cardiac rehabilitation
Yoga for secondary prevention of coronary heart disease
B.4 Psychological (4)
Psychological interventions for symptomatic management of non-specific chest pain in patients with normal coronary anatomy
Psychological interventions for coronary heart disease
Psychosocial interventions for smoking cessation in patients with coronary heart disease
Psychological and pharmacological interventions for depression in patients with coronary artery disease
B.5 Counselling/Education (2)
Patient education in the management of coronary heart disease
Sexual counselling for sexual problems in patients with cardiovascular disease
B.6 Percutaneous coronary interventions (6)
Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis
Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes
Transradial versus transfemoral approach for diagnostic coronary angiography and percutaneous coronary intervention in people with coronary artery disease
Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention
Transmyocardial laser revascularization versus medical therapy for refractory angina
Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease
B.7 Surgery (8)
B.7.1 Coronary Artery Bypass Grafting [CABG] (8)
Antithrombotic treatment following coronary artery bypass surgery: a network meta-analysis (protocol stage)
Off-pump versus on-pump coronary artery bypass grafting for ischaemic heart disease
Coronary artery bypass surgery versus medical therapy alone for ischaemic heart disease (protocol stage)
Prophylactic corticosteroids for cardiopulmonary bypass in adults
Percutaneous transluminal rotational atherectomy for coronary artery disease
Pre-operative intra aortic balloon pumps in patients undergoing coronary artery bypass grafting
Incentive spirometry for preventing pulmonary complications after coronary artery bypass graft
Hypothermia to reduce neurological damage following coronary artery bypass surgery
B.8 Organisational/Health System Interventions (3)
Internet-based interventions for the secondary prevention of coronary heart disease
Service organisation for the secondary prevention of ischaemic heart disease in primary care
Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease
B.9 Other Interventions (4)
Enhanced external counterpulsation for chronic angina pectoris
Remote ischaemic preconditioning for coronary artery bypass grafting (with or without valve surgery)
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
Ultrasound guidance for arterial (other than femoral) catheterisation in adults
C. Acute Coronary Syndromes/Unstable Angina (28)
C.1 Drugs (12)
C.1.1 Antiplatelets [aspirin; clopidogrel; glycoproteinIIb/IIIa inhibitors; ticlopidine] (2)
De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a network meta-analysis of randomised controlled trials (protocol stage)
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes
C.1.2 Anticoagulants [Heparin/Warfarin] (4)
Heparin versus placebo for non-ST elevation acute coronary syndromes
Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (protocol stage)
Vitamin K for improved anticoagulation control in patients receiving warfarin
C.1.3 Adrenergic Agents (2)
Beta-blockers for myocardial infarction (protocol stage)
Beta-blockers for suspected or diagnosed acute myocardial infarction
C.1.4 Antiarrhythmics (1)
Prophylactic lidocaine for myocardial infarction
C.1.5 Calcium Channel blockers (0)
C.1.6 Lipid Lowering Agents (1)
Statins for acute coronary syndrome
C.1.7 Nitrates (0)
C.1.8 Thrombolytics (0)
C.1.9 Vasodilators (0)
C.1.10 Other (2)
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome
Intravenous magnesium for acute myocardial infarction
C.2 Percutaneous Coronary Interventions (6)
Drug-eluting stents versus bare-metal stents for acute coronary syndrome
Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease
Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction
Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis
Percutaneous transluminal rotational atherectomy for coronary artery disease
Transradial versus transfemoral approach for diagnostic coronary angiography and percutaneous coronary intervention in people with coronary artery disease
C.3 Surgery (2)
C.3.1 Invasive versus conservative management (2)
Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction
Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
C.4 Complementary Treatments (2)
Danshen (Chinese medicinal herb) preparations for acute myocardial infarction
Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris
C.5 Organisational/Health System Interventions (1)
Bed rest for acute uncomplicated myocardial infarction
C.6 Other Treatments (5)
Hyperbaric oxygen therapy for acute coronary syndrome
Granulocyte colony stimulating factor therapy for acute myocardial infarction
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock
Oxygen therapy for acute myocardial infarction
Stem cell treatment for acute myocardial infarction
D. Heart Arrest (6)
D.1 Drugs (2)
Adrenaline and vasopressin for cardiac arrest
Aminophylline for bradyasystolic cardiac arrest in adults
D.2 Mechanical treatments (2)
Active chest compression-decompression for cardiopulmonary resuscitation
Mechanical versus manual chest compressions for cardiac arrest
D.3 Defibrillation (2)
Different methods of providing automatic external defibrillators to out-of-hospital cardiac arrests to prevent sudden cardiac death (protocol stage)
Biphasic versus monophasic waveforms for transthoracic defibrillation in out-of-hospital cardiac arrest
D.4 Organisational/Health System Interventions (0)
Pre-hospital interventions; coronary ambulances (0)
General public cardiopulmonary resuscitation training (0)
E. Abnormal Heart Rhythms (33)
E.1 Atrial fibrillation (20)
E.1.1Drugs (9)
E.1.1.1 ACE inhibitors (0)
E.1.1.2 Adrenergic agents (including Beta blockers) (0)
E.1.1.3 Antiarrhythmics (3)
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
Different rate-controlling agents for the management of atrial fibrillation with rapid ventricular rate in the emergency department: a network meta-analysis (protocol stage)
Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation
E.1.1.4 Calcium channel blockers (0)
E.1.1.5 Cardiac glycosides (0)
E.1.1.6 Diuretics (0)
E.1.1.7 Lipid lowering agents (including Statins) (0)
E.1.1.8 Nitrates (0)
E.1.1.9 Phosphodiesterase inhibitors (0)
E.1.1.10 Potassium channel blockers (0)
E.1.1.11 Thrombolytics / Fibrinolytics (6)
Antiplatelets [Aspirin / Glycoprotein IIb / IIIa inhibitors] (0)
Anticoagulants [Heparin / Warfarin] (6)
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Long-term antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease (protocol stage)
Self-monitoring and self-management of oral anticoagulation
Vitamin K for improved anticoagulation control in patients receiving warfarin
Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
Optimal loading dose of warfarin for the initiation of oral anticoagulation
Clopidigrel (0)
Ticlopidine (0)
E.1.1.12 Vasodilators (0)
E.1.2 Electrical/Pacing (1)
External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis (protocol stage)
E.1.3 Surgical/Catheter Treatments (4)
Concomitant atrial fibrillation surgery for people undergoing cardiac surgery
Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation
Catheter ablation for atrial fibrillation (protocol stage)
Catheter ablation for paroxysmal and persistent atrial fibrillation
E.1.4 Other interventions (6)
Clinical service organisation for adults with atrial fibrillation (protocol stage)
Exercise-based cardiac rehabilitation for adults with atrial fibrillation
External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis (protocol stage)
Interventions for alcohol cessation in people with atrial fibrillation (protocol stage)
Systematic screening for the detection of atrial fibrillation
Wearable cardiac monitoring using smart-devices for the detection of atrial fibrillation in adults (protocol stage)
E.2 Paroxysmal Tachicardia (0)
E.2.1 Drugs (0)
E.2.2 Electrical/Pacing (0)
E.3 Supraventricular Tachycardia (4)
E.3.1 Drugs (2)
Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia
Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction
E.3.2 Electrical/Pacing (0)
E.3.3 Other interventions (2)
The effectiveness of the modified Valsalva Manoeuvre for reversion of supraventricular tachycardia (protocol stage)
Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia
E.4 Ventricular Tachycardia (3)
E.4.1 Drugs (1)
Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death
E.4.2 Electrical/Pacing (2)
Catheter ablation versus escalation of antiarrhythmic medications for management of ventricular tachycardia in patients with ischaemic heart disease (protocol stage)
Implantable defibrillators versus medical therapy for cardiac channelopathies
E.5 Sick Sinus Syndrome (2)
E.5.1 Drugs (0)
E.5.2 Electrical/Pacing (2)
Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block
Drugs and pacemakers for vasovagal, carotid sinus and situational syncope
E.6 Heart Block (0)
E.6.1 Electrical/Pacing (0)
E.7 Other Arrhythmias (4)
Exercise-based cardiac rehabilitation for adult patients with an implantable cardioverter defibrillator
Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery
Transvenous versus subcutaneous implantable cardiac defibrillators for people at risk of sudden cardiac death (protocol stage)
F. Heart Failure (35)
F.1 Drugs (15)
F.1 Adrenergic Agents (0)
F.1.2 Beta blockers (2)
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction
Beta-blockers for congestive heart failure in children
F.1.3 Angiotensin converting enzyme (ACE) inhibitors (1)
Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction
F.1.4 Angiotensin II antagonists (1)
Angiotensin receptor blockers for heart failure
F.1.5 Antiarrhthymics (including Amiodarone; Lignocane) (0)
F.1.6 Antibiotics (0)
F.1.7 Anti-inflammatory agents (0)
F.1.8 Calcium channel blockers (0)
F.1.9 Cardiac glycosides (1)
Digitalis for treatment of heart failure in patients in sinus rhythm
F.1.10 Diuretics (2)
Continuous infusion versus bolus injection of loop diuretics in congestive heart failure
Continuous infusion versus bolus injection of loop diuretics for congestive heart failure (protocol stage)
F.1.11 Natiuretic peptides (1)
B-type natriuretic peptide-guided treatment for heart failure
F.1.12 Nitrates (1)
Nitrates for acute heart failure syndromes
F.1.13 Phosphodiesterase III inhibitors for heart failure (1)
Phosphodiesterase III inhibitors for heart failure
F.1.14 Potassium Channel blockers (0)
F.1.15 Thrombolytics/Fibrinolytics (including Clopidogrel, Ticlopidine) (1)
Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm
F.1.16 Anticoagulation (Heparin/Warfarin) (2)
Vitamin K for improved anticoagulation control in patients receiving warfarin
Anticoagulation versus placebo for heart failure in sinus rhythm
F.1.18 Vasodilators (0)
F.1.19 Neprilysin inhibitors (1)
LCZ696 (sacubitril/valsartan) for patients with heart failure (protocol stage)
F.1.20 Others (1)
Treatment for hyperkalaemia in heart failure: a network meta-analysis (protocol stage)
F.2 Surgery (1)
F.2.1 Heart Transplantation (1)
Immunosuppressive T-cell antibody induction for heart transplant recipients
F.2.2 Myomectomy (0)
F.3 Ventricular assist devices (2)
Exercise-based cardiac rehabilitation for people with implantable ventricular assist devices
Mechanical assist devices for acute cardiogenic shock
F.4 Electrical/Pacing (1)
Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy
F.5 Lifestyle (0)
F.5.1 Diet (0)
F.6 Rehabilitation (4)
Exercise-based cardiac rehabilitation for adults with heart failure
Exercise-based cardiac rehabilitation in heart transplant recipients
Home-based versus centre-based cardiac rehabilitation
Interventions to promote patient utilisation of cardiac rehabilitation
F.7 Psychological (1)
Psychological interventions for depression in heart failure
F.8 Complementary Treatments (2)
Coenzyme Q10 for heart failure
Hawthorn extract for treating chronic heart failure
F.9 Organisational/Health system interventions (2)
Disease management interventions for heart failure
Structured telephone support or non-invasive telemonitoring for patients with heart failure
F.10 Other interventions (7)
Advance care planning for adults with heart failure
Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Implantable device monitoring versus usual care for managing individuals with heart failure (protocol stage)
Ivabradine as adjuvant treatment for chronic heart failure
mHealth education interventions in heart failure
Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
G. Acute Heart Failure (2)
Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema
Ultrafiltration for acute heart failure
H. Chagas Cardiomyopathy (3)
H.1 Drugs (3)
Trypanocidal drugs for chronic asymptomatic infection
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy
Trypanocidal drugs for late-stage, symptomatic Chagas disease ( infection)
H.2 Surgery (0)
H.3 Other (0)
I. Dilated cardiomyopathy (1)
I.1 Drugs (0)
I.1.1 ACE Inhibitors (0)
I.1.2 Adrenergic agents (including beta blockers) (0)
I.1.3 Calcium channel blockers (0)
I.1.4 Nitrates (0)
I.2 Surgery (0)
I.3 Electrical/Pacing (0)
I.4 Other (1)
Stem cell therapy for dilated cardiomyopathy
J. Hypertrophic Cardiomyopathy (1)
J.1 Drugs (0)
J.1.1 Antiarrhythmics (0)
J.1.2 Adrenergic agents (0)
J.1.3 Betablockers (0)
J.1.4 Calcium channel blockers (0)
J.2 Surgery (0)
J.3 Electrical/Pacing (1)
Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy
J.4 Psychological (0)
J.5 Counselling/Education (0)
J.6 Complimentary treatments (0)
J.7 Other (0)
K. Myocarditis (2)
K.1 Drugs (2)
Corticosteroids for viral myocarditis
Intravenous immunoglobulin for presumed viral myocarditis in children and adults
K.2 Complementary treatments (0)
K.3 Other (0)
L. Pericardial Diseases (2)
L.1 Drugs (2)
Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure
Colchicine for pericarditis
M. Rheumatic Heart Disease (2)
M.1 Drugs (2)
Anti-inflammatory treatment for carditis in acute rheumatic fever
Penicillin for secondary prevention of rheumatic fever
N. Heart Valve Disease (17)
N.1 Drugs (12)
N1.1 Antibiotic prophylaxis (1)
Pharmacological interventions for the treatment of aortic root and heart valve disease (protocol stage)
N.1.2 Adrenergic agents (1)
Pharmacological interventions for the treatment of aortic root and heart valve disease (protocol stage)
N1.3 Betablockers (1)
Pharmacological interventions for the treatment of aortic root and heart valve disease (protocol stage)
N.1.4 Cardiac glycosides (1)
Pharmacological interventions for the treatment of aortic root and heart valve disease (protocol stage)
N.1.5 Lipid lowering agents (2)
Pharmacological interventions for the treatment of aortic root and heart valve disease (protocol stage)
Statins for aortic valve stenosis
N.1.6 Anticoagulants (6)
Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion (protocol stage)
Antiplatelet and anticoagulation for patients with prosthetic heart valves
Pharmacological interventions for the treatment of aortic root and heart valve disease (protocol stage)
Self-monitoring and self-management of oral anticoagulation
Vitamin K for improved anticoagulation control in patients receiving warfarin
Optimal loading dose of warfarin for the initiation of oral anticoagulation
N.2 Rehabilitation (1)
Exercise-based cardiac rehabilitation for adults after heart valve surgery
N.3 Surgery (4)
Limited versus full sternotomy for aortic valve replacement
Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis (protocol stage)
Transcatheter and surgical intervention for secondary mitral regurgitation (protocol stage)
Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk
O. Endocarditis (2)
O.1 Drugs (1)
A comparison of different antibiotic regimens for the treatment of infective endocarditis
O.2 Complementary treatments (0)
O.3 Surgery (1)
O.3.1 Balloon valvuloplasty (0)
O.3.2 Valve repair (1)
Leukodepletion for patients undergoing heart valve surgery
O.3.3 Valve replacement (0)
O.4 Other interventions (0)
W. Other (1)
COVID-19 and its cardiovascular effects: a systematic review of prevalence studies
P. Congenital Heart Abnormalities (11)
P.1 Drugs (4)
Antibiotics for brain abscesses in people with cyanotic congenital heart disease
Beta-blockers for preventing aortic dissection in Marfan syndrome
Beta-blockers for congestive heart failure in children
Inotropes for the prevention of low cardiac output syndrome and mortality for paediatric patients undergoing surgery for congenital heart disease: a network meta-analysis (protocol stage)
P.2 Lifestyle (1)
Physical activity interventions for people with congenital heart disease
P.3 Surgery (5)
Red cell transfusion management for patients undergoing cardiac surgery for congenital heart disease
Inotropes for the prevention of low cardiac output syndrome and mortality for paediatric patients undergoing surgery for congenital heart disease: a network meta-analysis (protocol stage)
Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease
Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease
Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass
P.4 Psychological (1)
Psychological interventions for depression in adolescent and adult congenital heart disease
P.5 Complementary treatments (0)
Q. Heart Surgery [Not specific to disease areas above] (10)
High versus low blood pressure targets for cardiac surgery while on cardiopulmonary bypass
Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta-analysis (protocol stage)
Early versus late surgical start times for on-pump cardiac surgery  (protocol stage)
Effects of interventions targeting the systemic inflammatory response to cardiac surgery on clinical outcomes in adults (protocol stage)
Fresh frozen plasma for cardiovascular surgery
Interventions to prevent surgical site infection in adults undergoing cardiac surgery (protocol stage)
Mediastinal chest drain clearance for cardiac surgery
Preoperative physical therapy for elective cardiac surgery patients
Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery (protocol stage)
Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding
R. Other drug treatments [not specified to other topics] (0)
V. Cardiac Monitoring (1)
Wearable cardiac monitoring using smart-devices for the detection of atrial fibrillation in adults (protocol stage)
S. Risk Stratification (2)
The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery
Heart failure symptoms as predictors of hospital admission, readmission and all-cause mortality (protocol stage)
T. Consumer_cardiac rehabilitation (0)
U. Consumer_general (0)